InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (8 ops.)
Insider track record
CEODisclosed buys
2
Disclosed sells
8
T+90 hit rate
25%
T+90 mean return
-24.7%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Koenig Sheldon L., Chairman & CEO. Officer active across 1 company, notably Esperion Therapeutics, Inc.. Cumulatively, 18 reports have been published. Split: 2 buys · 8 sells. Total volume traded: €227k. History available since 17 May 2021. The latest transaction was filed on 18 March 2025 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations18 total
13,047 shares@ US$1.5047.9% of flowCommon StockSEC:0001628280-25-013810:0
840,000 shares0Common StockSEC:0001628280-25-013199:0
12,447 shares@ US$2.46612.8% of flowCommon StockSEC:0001628280-24-051868:0
14,550 shares@ US$1.79610.3% of flowCommon StockSEC:0001628280-24-040787:0
454,000 shares0Common StockSEC:0001628280-24-011485:0
20,000 shares@ US$1.259610.1% of flowCommon StockSEC:0001628280-23-017231:0
Ideal exit: 3 Feb 2024 (T+270)
6,999 shares@ US$1.7835.2% of flowCommon StockSEC:0001628280-23-008610:0
105,000 shares0Common StockSEC:0001628280-23-007969:0
5,441 shares@ US$5.05611.3% of flowCommon StockSEC:0001628280-23-006991:0
3,394 shares@ US$6.93810.3% of flowCommon StockSEC:0001628280-22-025217:0
8,606 shares@ US$5.804121.4% of flowCommon StockSEC:0001628280-22-021568:0
Ideal exit: 2 May 2023 (T+270)
4,552 shares@ US$4.9910.0027% mcap90.1% of flowCommon StockSEC:0001628280-22-017642:0
571 shares@ US$4.580.0003% mcap9.9% of flowCommon StockSEC:0001628280-22-006733:0
116,000 shares0Common StockSEC:0001628280-22-006405:0
26,700 shares0Common StockSEC:0001628280-21-021009:0
26,700 shares0Common StockSEC:0001628280-21-021009
20,000 shares0Common StockSEC:0001628280-21-010605
20,000 shares0Common StockSEC:0001628280-21-010605:0
18 of 18 declarations
About Koenig Sheldon L.
Koenig Sheldon L. is the President and CEO of Esperion Therapeutics, Inc. He leads the company by overseeing operations and defining the business strategy. Koenig is responsible for innovation and the development of new treatments, thereby contributing to Esperion's mission of transforming patients' lives. His leadership is essential in achieving the company's growth and research objectives.
